StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise focused on the development and commercialization of proprietary molecular diagnostic tests. These tests are primarily designed for the early detection of diseases and to facilitate personalized health management, with a particular emphasis on oncology-related conditions within the United States and Canada. At the core of their offerings is the proprietary Sentinel Principle platform technology, which specializes in identifying novel biomarkers from whole blood samples. The company's lead product, Aristotle, is an innovative multi-cancer panel test capable of simultaneously screening for numerous cancer types from a single blood sample, demonstrating high sensitivity and specificity for each detected cancer. StageZero's product portfolio also encompasses ColonSentry, a blood test that assesses an individual's current risk of colorectal cancer; COVID-19 polymerase chain reaction (PCR) testing and detailed blood test analysis; the Prostate Health Index, a screening tool for prostate cancer; and BreastSentry, a test designed to determine a woman's risk of developing breast cancer. Established in 1998, the company maintains its headquarters in Richmond Hill, Canada.
—
StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise focused on the development and commercialization of proprietary molecular diagnostic tests. These tests are primarily designed for the early detection of diseases and to facilitate personalized health management, with a particular emphasis on oncology-related conditions within the United States and Canada. At the core of their offerings is the proprietary Sentinel Principle platform technology, which specializes in identifying novel biomarkers from whole blood samples. The company's lead product, Aristotle, is an innovative multi-cancer panel test capable of simultaneously screening for numerous cancer types from a single blood sample, demonstrating high sensitivity and specificity for each detected cancer. StageZero's product portfolio also encompasses ColonSentry, a blood test that assesses an individual's current risk of colorectal cancer; COVID-19 polymerase chain reaction (PCR) testing and detailed blood test analysis; the Prostate Health Index, a screening tool for prostate cancer; and BreastSentry, a test designed to determine a woman's risk of developing breast cancer. Established in 1998, the company maintains its headquarters in Richmond Hill, Canada.
—
Daily adjusted close
StageZero Life Sciences Ltd. is a vertically integrated healthcare enterprise focused on the development and commercialization of proprietary molecular diagnostic tests. These tests are primarily designed for the early detection of diseases and to facilitate personalized health management, with a particular emphasis on oncology-related conditions within the United States and Canada. At the core of their offerings is the proprietary Sentinel Principle platform technology, which specializes in identifying novel biomarkers from whole blood samples. The company's lead product, Aristotle, is an innovative multi-cancer panel test capable of simultaneously screening for numerous cancer types from a single blood sample, demonstrating high sensitivity and specificity for each detected cancer. StageZero's product portfolio also encompasses ColonSentry, a blood test that assesses an individual's current risk of colorectal cancer; COVID-19 polymerase chain reaction (PCR) testing and detailed blood test analysis; the Prostate Health Index, a screening tool for prostate cancer; and BreastSentry, a test designed to determine a woman's risk of developing breast cancer. Established in 1998, the company maintains its headquarters in Richmond Hill, Canada.